Market Research Report
Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
|Published by||GlobalData||Product code||294517|
|Published||Content info||87 Pages
|Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023|
|Published: October 31, 2014||Content info: 87 Pages||
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Eylea (aflibercept) is a recombinant fusion protein co-developed by Regeneron and Bayer AG. Eylea acts as a VEGF inhibitor and is approved for the treatment of wAMD and ME-CRVO in all 7MM, and for DME in the US and EU. The developers are also attempting to gain approval for Eylea for DME in Japan, and for ME-BRVO throughout in the EU and Japan.